Accueil   Diary - News   All news Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions

Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions

 

 

Lyon, France June 14th, 2018 – 6:00 pm CET – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of approved proteins, today announced that six abstracts covering its diabetes portfolio have been accepted for presentation at the upcoming 78th Scientific Sessions of the American Diabetes Association® being held June 22-26, 2018 in Orlando, Florida.

 


Adocia’s portfolio of injectable treatments for diabetes, featuring six clinical-stage products and two preclinical products, is enabled by the proprietary BioChaperone® technology, designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use.

 

 

Read the full press release